Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Cell-mediated Immune Responses01:40

Cell-mediated Immune Responses

83.1K
Overview
83.1K
Tissue Transplantation01:24

Tissue Transplantation

816
Tissue transplantation is a significant medical procedure involving the transfer of cells, tissues, or organs from a donor to a recipient, with the primary aim of restoring lost functions. This procedure is crucial in treating a broad spectrum of diseases, including kidney diseases, liver failure, heart disease, and certain types of cancers.
The Biology of Tissue Transplantation
The biology of tissue transplantation hinges on the Major Histocompatibility Complex (MHC) molecules. These molecules...
816
T Cell Types and Functions01:24

T Cell Types and Functions

2.0K
When T cells with CD4 markers are activated, they give rise to two types of effector cells: helper T cells and regulatory T cells. Meanwhile, T cells with CD8 markers differentiate into effector cytotoxic T cells. The differentiation of CD4 T cells into helper T cell subsets, such as Th1, Th2, and Th17 cells, is dependent on the antigen type, antigen-presenting cell, and regulatory cytokines.
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
2.0K
Kidney Transplant I: Introduction01:28

Kidney Transplant I: Introduction

269
A kidney transplant is a surgical approach that involves replacing a non-functioning kidney with a healthy one from a donor. This procedure is often a treatment option for end-stage renal disease (ESRD) patients. The method requires careful recipient selection, including evaluating various medical and psychosocial factors. These criteria vary between transplant centers but generally include assessments of the patient's overall health, adherence to medical recommendations, and lifestyle...
269

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Pneumocystis jirovecii pneumonia after liver transplantation in France: retrospective multicenter case series and survey on prophylaxis use.

Infectious diseases now·2026
Same author

Pre-liver transplant assessment of patients with acute-on-chronic liver failure: An international survey.

JHEP reports : innovation in hepatology·2026
Same author

In Remembrance of Professor Zelig Eshhar: <i>A Life Committed to CAR-T</i>.

Human gene therapy·2026
Same author

A symposium update on the key perspectives in systemic sclerosis and systemic lupus erythematosus.

Journal of translational autoimmunity·2026
Same author

Opposing Association of Lung Neutrophils and PD-L1<sup>+</sup> Monocytes in Age-Related Severity of SARS-CoV-2 Infection.

Aging cell·2026
Same author

Liver Transplantation for HBV-Related Disease in France: NUC Type Before LT Is Associated With Patient Survival.

Liver international : official journal of the International Association for the Study of the Liver·2026

Related Experiment Video

Updated: Dec 27, 2025

In Vitro and In Vivo Assessment of T, B and Myeloid Cells Suppressive Activity and Humoral Responses from Transplant Recipients
18:48

In Vitro and In Vivo Assessment of T, B and Myeloid Cells Suppressive Activity and Humoral Responses from Transplant Recipients

Published on: August 12, 2017

14.8K

Regulatory T cells in solid organ transplantation.

Muhammad Atif1,2,3,4, Filomena Conti2, Guy Gorochov1

  • 1Sorbonne Université Inserm U1135 Centre d'Immunologie et des Maladies Infectieuses (CIMI-Paris) Hôpital Pitié-Salpêtrière AP-HP Paris France.

Clinical & Translational Immunology
|February 28, 2020
PubMed
Summary

Achieving graft tolerance is crucial for transplantation. This review explores regulatory T (Treg) cell therapy, focusing on clinical trials and the need for understanding Treg cell heterogeneity to improve patient outcomes.

Keywords:
FOXP3Tregclinical trialregulatory T cellssafetytransplant

More Related Videos

Trans-vivo Delayed Type Hypersensitivity Assay for Antigen Specific Regulation
11:49

Trans-vivo Delayed Type Hypersensitivity Assay for Antigen Specific Regulation

Published on: May 2, 2013

16.5K
Regulatory T cells: Therapeutic Potential for Treating Transplant Rejection and Type I Diabetes
16:26

Regulatory T cells: Therapeutic Potential for Treating Transplant Rejection and Type I Diabetes

Published on: August 20, 2007

6.1K

Related Experiment Videos

Last Updated: Dec 27, 2025

In Vitro and In Vivo Assessment of T, B and Myeloid Cells Suppressive Activity and Humoral Responses from Transplant Recipients
18:48

In Vitro and In Vivo Assessment of T, B and Myeloid Cells Suppressive Activity and Humoral Responses from Transplant Recipients

Published on: August 12, 2017

14.8K
Trans-vivo Delayed Type Hypersensitivity Assay for Antigen Specific Regulation
11:49

Trans-vivo Delayed Type Hypersensitivity Assay for Antigen Specific Regulation

Published on: May 2, 2013

16.5K
Regulatory T cells: Therapeutic Potential for Treating Transplant Rejection and Type I Diabetes
16:26

Regulatory T cells: Therapeutic Potential for Treating Transplant Rejection and Type I Diabetes

Published on: August 20, 2007

6.1K

Area of Science:

  • Immunology
  • Transplantation Science
  • Cellular Therapy

Background:

  • Graft tolerance is a major goal in transplantation, aiming to reduce chronic allograft dysfunction and immunosuppression side effects.
  • Regulatory T (Treg) cells are key in immune modulation and tissue homeostasis, but their heterogeneity and complex functions remain incompletely understood.
  • Advancements in immunophenotyping and genomic sequencing reveal greater complexity in Treg cell biology.

Purpose of the Study:

  • To review the current understanding of Treg cell immunobiology, emphasizing heterogeneity.
  • To discuss first-in-man clinical trials using Treg cells as adoptive therapy from a translational safety perspective.
  • To identify critical knowledge gaps for future research in Treg cell therapy.

Main Methods:

  • Review of existing literature on Treg cell immunobiology.
  • Analysis of translational data from Treg cell adoptive therapy clinical trials.
  • Discussion of advanced immunophenotyping and genomic sequencing findings.

Main Results:

  • Treg cells are functionally diverse, and their heterogeneity is more complex than previously recognized.
  • Early-phase clinical trials using Treg cell therapy have commenced, providing initial safety and feasibility data.
  • Significant knowledge gaps persist regarding Treg cell biology and therapeutic application.

Conclusions:

  • A comprehensive understanding of Treg cell heterogeneity is essential for safe and effective Treg cell-based therapies.
  • Translational research and clinical trials are advancing Treg cell therapy, with a focus on safety.
  • Future studies must address identified knowledge gaps to optimize Treg cell therapy for transplantation.